RAPT RAPT Therapeutics, Inc.

Nasdaq rapt.com


$ 30.00 $ 1.90 (7.03 %)    

Thursday, 16-Oct-2025 17:48:36 EDT
QQQ $ 598.07 $ -2.23 (-0.37 %)
DIA $ 458.55 $ -3.15 (-0.68 %)
SPY $ 658.84 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 402.04 $ 9.06 (2.34 %)
$ 28.93
$ 27.26
$ 24.00 x 1
$ 31.50 x 100
$ 27.07 - $ 29.00
$ 5.67 - $ 32.35
161,837
na
478.44M
$ 1.54
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-06-2025 01-01-1970 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-07-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-11-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-14-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-10-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-11-2021 06-30-2021 10-Q
18 05-11-2021 03-31-2021 10-Q
19 03-11-2021 12-31-2020 10-K
20 11-16-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 12-11-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-initiates-coverage-on-rapt-therapeutics-with-overweight-rating-announces-price-target-of-35

Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces P...

 clear-street-maintains-buy-on-rapt-therapeutics-raises-price-target-to-41

Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $2...

 rapt-wins-fda-approval-to-test-food-allergy-drug-in-mid-stage-study

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

 leerink-partners-upgrades-rapt-therapeutics-to-outperform-raises-price-target-to-37

Leerink Partners analyst Thomas Smith upgrades RAPT Therapeutics (NASDAQ: RAPT) from Market Perform to Outperform and raises...

 ubs-maintains-neutral-on-rapt-therapeutics-raises-price-target-to-9

UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and raises the price target from $8 to $9.

 wells-fargo-maintains-overweight-on-rapt-therapeutics-lowers-price-target-to-38

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and lowers the price target from $...

 rapt-therapeutics-q2-eps-065-misses-063-estimate

RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $...

 jp-morgan-upgrades-rapt-therapeutics-to-neutral-announces-14-price-target

JP Morgan analyst Anupam Rama upgrades RAPT Therapeutics (NASDAQ:RAPT) from Underweight to Neutral and announces $14 price t...

 lifesci-capital-initiates-coverage-on-rapt-therapeutics-with-outperform-rating-announces-price-target-of-31

LifeSci Capital initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Outperform rating and announces Price Target of ...

 hc-wainwright--co-maintains-buy-on-rapt-therapeutics-raises-price-target-to-27

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price targe...

 rapt-therapeutics-to-effect-1-for-8-reverse-stock-split

-SEC Filing

 ubs-maintains-neutral-on-rapt-therapeutics-lowers-price-target-to-1

UBS analyst Eliana Merle maintains RAPT Therapeutics (NASDAQ:RAPT) with a Neutral and lowers the price target from $2 to $1.

 hc-wainwright--co-assumes-rapt-therapeutics-at-buy-announces-price-target-of-6

HC Wainwright & Co. analyst Emily Bodnar assumes RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price T...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION